Allogene (ALLO) news
Recent news
Allogene Therapeutics files $500M mixed securities shelf
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has filed a mixed securities shelf registration with the Securities and Exchange Commission (SEC), allowing the company to offer and sell up to $500 million in securities over time, subject to market conditions and investor demand. This filing expands the…
AInvest Wire · Aug 12, 2026Allogene 2Q loss/share 13c vs. loss/share 23c y/y
AInvest Wire · Aug 12, 2026Allogene Therapeutics: closes $35 mln financing to advance off--shelf CAR-T therapies for T-cell cancers
AInvest Wire · Jul 8, 2026Gaodi proposes rights issue to raise up to HK$24.99 mln
Gaodi, a listed company in Hong Kong, has proposed a rights issue to raise up to HK$24.99 million, according to recent disclosures. The move is part of the company’s strategy to strengthen its financial position and support ongoing operations. The rights issue will allow existing shareholders to…
AInvest Wire · Jun 5, 2026Allogene Therapeutics names Zachary Roberts as CEO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has appointed Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development, a role that includes oversight of the company’s clinical and pre-clinical programs. Dr. Roberts succeeds Rafael Amado, M.D., who has stepped down to…
AInvest Wire · May 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.